Supercharge Your Innovation With Domain-Expert AI Agents!

Use of Dasainib and Quercetin pharmaceutical composition in preparing medicine for preventing and/or treating side effects of glucocorticoid

A technology of glucocorticoid and dasatinib, applied in the field of medicine, can solve the problem of eliminating the side effects of glucocorticoid without dasatinib and quercetin

Active Publication Date: 2020-10-16
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the prior art, there is no relevant report on the use of dasatinib and quercetin to eliminate the side effects of glucocorticoids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Dasainib and Quercetin pharmaceutical composition in preparing medicine for preventing and/or treating side effects of glucocorticoid
  • Use of Dasainib and Quercetin pharmaceutical composition in preparing medicine for preventing and/or treating side effects of glucocorticoid
  • Use of Dasainib and Quercetin pharmaceutical composition in preparing medicine for preventing and/or treating side effects of glucocorticoid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1: Construction of animal model

[0051] 1. Establishment of mouse PDE model

[0052] Pregnant mice were treated with dexamethasone during the 12th to 14th day of pregnancy to establish a prenatal application of dexamethasone (PDE) model. As briefly outlined below, 8-12 week old C57BL / 6 female mice were mated with male mice overnight. The day when the vaginal suppository appeared was set as GD (gestational day) 0, and the pregnant mice were randomly divided into PDE group or control group. Dexamethasone sodium phosphate (Cat.2392-39-4, "Tianxin") was given subcutaneously (1.2 mg / kg / d) during GD 12-14 to establish a PDE mouse model, and this group of mice was called the model group . To establish a control for the PDE model, during GD 12-14, a control group of pregnant mice was treated with daily subcutaneous injections of the same amount of solvent (normal saline), and this group of mice was called the control group. In order to avoid data bias caused by ...

Embodiment 2

[0055] Embodiment 2: Study on bone morphology of progeny mice

[0056] 1. Specimen fixation and decalcification

[0057] The offspring mice were killed by cervical dislocation after anesthesia, and the femur and tibia were taken out, respectively fixed in 4% paraformaldehyde, decalcified with 0.5M ethylenediaminetetraacetic acid (EDTA, pH 7.4), and passed through a gradient concentration of ethanol / 30% Paraffin-embedded / frozen-embedded after sucrose dehydration, so as to study the growth morphology of the long bones of offspring mice.

[0058] 2. Senescence-associated β-galactosidase (SA-β-Gal) staining

[0059] SA-β-Gal staining steps:

[0060] (1) Frozen sections were thawed in a 37°C oven for 30 minutes.

[0061] (2) Prepare β-Galactosidase staining solution: 930 μL staining solution + 50 μL X-gal solution (20 mg / mL, store at -20°C in the dark) + 10 μL A solution + 10 μL B solution.

[0062] (3) The slices were washed once with PBS, 5 minutes each time.

[0063] (4) Ad...

Embodiment 3

[0116] Flow cytometric analysis and statistical analysis of embodiment 3PDE progeny mice

[0117] Flow Cytometry

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to the use of a Dasainib and Quercetin pharmaceutical composition in preparing a medicine for preventing and / or treating the side effects of glucocorticoid. Although prenatal use of dexamethasone has many benefits to newborns, the harms cannot be ignored. Glucocorticoid can cause delayed embryonic development and related diseases after birth of offspring. The pharmaceutical composition Dasainib and Quercetin can improve the bone phenotype of the offspring and the inhibitory effect of glucocorticoid applicationon BMSCs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of a pharmaceutical composition of dasatinib and quercetin in the preparation of drugs for preventing and / or treating side effects of glucocorticoids. Background technique [0002] Glucocorticoids belong to steroidal compounds and are a metabolic regulation hormone synthesized and secreted by the adrenal cortex zona. Glucocorticoids mainly affect the metabolism of sugar, protein and fat at physiological doses, and have anti-inflammatory, immunosuppressive, antitoxin, anti-allergic, anti-shock and other effects at pharmacological doses. Glucocorticoids have extensive effects and influences on the functions of various organs of the body. For example, long-term large-dose administration can cause hypertension, hypokalemia, osteoporosis, peptic ulcer bleeding or perforation, poor wound healing, induced Or aggravate side effects and complications such as infection, mental ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/506A61K31/352A61P3/04A61P25/00A61P5/00A61P25/24A61P25/28A61P3/06A61P3/10A61P9/00A61P21/00A61P19/10A61P19/08A61P1/00A61P19/00A61P7/04A61P27/12
CPCA61K31/352A61K31/506A61P1/00A61P3/04A61P3/06A61P3/10A61P5/00A61P7/04A61P9/00A61P19/00A61P19/08A61P19/10A61P21/00A61P25/00A61P25/24A61P25/28A61P27/12A61K2300/00
Inventor 张先荣余斌苏剑文
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com